|
IL86278A
(en)
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
|
US6790614B1
(en)
|
1999-11-19 |
2004-09-14 |
Novartis Ag |
Selectable cell surface marker genes
|
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
|
|
EP2646469B1
(en)
|
2010-12-01 |
2017-11-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Chimeric rabbit/human ror1 antibodies
|
|
EP2814846B1
(en)
*
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
SG10201808811QA
(en)
|
2014-04-10 |
2018-11-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Method and compositions for cellular immunotherapy
|
|
WO2015161835A1
(de)
*
|
2014-04-20 |
2015-10-29 |
New / Era / Mabs Gmbh |
Biomoleküle freisetzende zelle und deren selektion mittels eines oberflächenproteins
|
|
WO2015164759A2
(en)
*
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Mnd promoter chimeric antigen receptors
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
SG10201913151TA
(en)
|
2015-09-09 |
2020-03-30 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Genetic engineering of macrophages for immunotherapy
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
CN106967684A
(zh)
|
2016-01-13 |
2017-07-21 |
北京马力喏生物科技有限公司 |
共表达抗EGFRvIII嵌合抗原受体和无功能EGFR受体的转基因淋巴细胞及其用途
|
|
CN106967681B
(zh)
|
2016-01-13 |
2020-06-05 |
北京马力喏生物科技有限公司 |
治疗脑胶质母细胞瘤的治疗组合物
|
|
CN107586342A
(zh)
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及其应用
|
|
CN107586341A
(zh)
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及免疫检查点抑制分子的共表达及应用
|
|
CN108342361B
(zh)
|
2017-01-25 |
2020-12-22 |
北京马力喏生物科技有限公司 |
治疗间质素阳性肿瘤的治疗组合物
|
|
CN108342360A
(zh)
|
2017-01-25 |
2018-07-31 |
北京马力喏生物科技有限公司 |
共表达抗msln嵌合抗原受体和无功能egfr的转基因淋巴细胞及其用途
|
|
WO2018200582A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
|
US11149073B2
(en)
|
2017-04-28 |
2021-10-19 |
Julius-Maximilians-Universität Würzburg |
ROR1-specific chimeric antigen receptors (CAR) with humanized targeting domains
|
|
EP3692057B9
(en)
|
2017-10-03 |
2023-10-04 |
Precision BioSciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
|
EP3723774A4
(en)
|
2017-12-15 |
2021-09-08 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
|
|
AU2019216269B2
(en)
|
2018-01-30 |
2025-05-01 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
|
|
US10663465B2
(en)
*
|
2018-03-05 |
2020-05-26 |
The Hong Kong University Of Science And Technology |
Disruption of EGFR-SAR1 interaction for cancer treatment
|
|
CN110526983B
(zh)
|
2018-05-24 |
2022-02-11 |
北京马力喏生物科技有限公司 |
改良型抗cd19 car-t细胞
|
|
CA3105816A1
(en)
|
2018-07-10 |
2020-01-16 |
Precigen, Inc. |
Ror-1 specific chimeric antigen receptors and uses thereof
|
|
US20210322473A1
(en)
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
KR20210074274A
(ko)
|
2018-08-06 |
2021-06-21 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물
|
|
CN112996819B
(zh)
|
2018-08-16 |
2025-11-04 |
纪念斯隆-凯特琳癌症中心 |
细胞分选系统及使用方法
|
|
CN112930186A
(zh)
|
2018-08-16 |
2021-06-08 |
纪念斯隆-凯特琳癌症中心 |
基于亮氨酸拉链的组合物和使用方法
|
|
EP3856769A4
(en)
|
2018-09-28 |
2022-08-17 |
Memorial Sloan Kettering Cancer Center |
IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
|
|
KR20210072797A
(ko)
|
2018-10-05 |
2021-06-17 |
세인트 안나 킨더크렙스포르슝 |
키메라 항원 수용체(car) 그룹
|
|
CN111088231A
(zh)
|
2018-10-24 |
2020-05-01 |
艾生命序公司 |
Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
|
|
EP4578507A3
(en)
|
2018-11-01 |
2025-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
JP7352307B2
(ja)
|
2019-03-15 |
2023-09-28 |
阿思科力（蘇州）生物科技有限公司 |
自殺遺伝子を持つｒｏｂｏ１ ｃａｒ－ｎｋ細胞、その製造方法及び使用
|
|
WO2021222479A1
(en)
|
2020-04-28 |
2021-11-04 |
Lyell Immunopharma, Inc. |
Methods for culturing cells
|
|
MX2022014203A
(es)
|
2020-05-12 |
2023-02-22 |
Lyell Immunopharma Inc |
Espaciadores de receptores de antígenos quiméricos (car).
|
|
EP4298230A1
(en)
|
2021-02-25 |
2024-01-03 |
Lyell Immunopharma, Inc. |
Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
|
|
AU2022226660A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Methods for culturing cells
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|